ADA: Orforglipron Reduces Glycated Hemoglobin in Early Type 2 Diabetes
By Elana Gotkine HealthDay Reporter
WEDNESDAY, June 25, 2025 -- The oral small-molecule glucagon-like peptide-1 receptor agonist, orforglipron, reduced glycated hemoglobin (HbA1c) over 40 weeks in adults with early type 2 diabetes, according to a study published online June 21 in the New England Journal of Medicine to coincide with the annual meeting of the American Diabetes Association, held from June 20 to 23 in Chicago.
Julio Rosenstock, M.D., from the Velocity Clinical Research Center at Medical City Dallas, and colleagues conducted a phase 3 trial involving participants with type 2 diabetes treated only with diet and exercise, an HbA1c level of ≥7.0 to ≤9.5 percent, and a body mass index of at least 23.0 kg/m2. Five hundred fifty-nine participants were randomly assigned to receive orforglipron (3 mg, 12 mg, or 36 mg) or placebo once daily for 40 weeks.
The researchers found that the estimated mean change from baseline in the HbA1c was −1.24, −1.47, −1.48, and −0.41 percentage points at week 40 with the 3-mg, 12-mg, and 36-mg doses and with placebo, respectively. With respect to this primary end point, all three doses of orforglipron were superior to placebo. At week 40, the mean Hb1Ac levels were 6.5 to 6.7 percent with orforglipron. From baseline to week 40, the percent change in body weight was −4.5, −5.8, and −7.6 percent with the 3-mg, 12-mg, and 36-mg doses, respectively, and −1.7 percent with placebo. Mild-to-moderate gastrointestinal events were the most common adverse events with orforglipron.
"Significant and clinically meaningful reductions in the glycated hemoglobin level were observed with all three doses of orforglipron, and the changes were significantly greater than those with placebo," the authors write.
Several authors disclosed ties to biopharmaceutical companies, including Eli Lilly, which is developing orforglipron and funded the study.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2025
Read this next
Broader Formulary Coverage Linked to Lower Odds of MS Relapse
FRIDAY, Aug. 8, 2025 -- Broader formulary coverage is associated with lower odds of multiple sclerosis (MS) relapse among Medicare beneficiaries, according to a study published...
'Heart Age' Often Older Than Chronological Age
FRIDAY, Aug. 8, 2025 -- The Predicting Risk of Cardiovascular Disease Events (PREVENT) equation risk age is older than chronological age on average, with greater discordance for...
Nonlinear Inverse Association Seen for Step Count, Peak Cadence With MACE
THURSDAY, Aug. 7, 2025 -- There are nonlinear, inverse associations for step count and peak cadence with the risk for major adverse cardiovascular events (MACE) among individuals...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.